share_log

Clover Health | 8-K: Clover Health Reports Second Quarter 2024 Financial Results; Improves Full-Year Guidance on Strong Performance

Clover Health | 8-K: Clover Health Reports Second Quarter 2024 Financial Results; Improves Full-Year Guidance on Strong Performance

Clover Health | 8-K：三葉草健康公佈2024年第二季度財務業績；改善了全年強勁業績指引
美股SEC公告 ·  08/06 04:12

牛牛AI助理已提取核心訊息

Clover Health reported strong Q2 2024 results, with total revenue growing 11% YoY to $356.3M. The company achieved its first quarter of GAAP net income as a public company, reporting $7.2M compared to a $28.9M loss in Q2 2023. Adjusted EBITDA improved to $36.2M from $9.9M YoY.Insurance revenue rose 11% YoY to $349.9M, driven by strong member retention and growth. Insurance MCR improved to 71.3% from 77.2% YoY. The company's balance sheet strengthened, with $482.8M in cash and investments as of June 30, 2024.Based on strong performance, Clover Health raised its full-year 2024 guidance. It now expects Insurance revenue of $1.35B-$1.375B and Adjusted EBITDA of $50M-$65M. The company's recent Star Rating increase to 3.5 for the 2025 payment year is expected to improve long-term profitability.
Clover Health reported strong Q2 2024 results, with total revenue growing 11% YoY to $356.3M. The company achieved its first quarter of GAAP net income as a public company, reporting $7.2M compared to a $28.9M loss in Q2 2023. Adjusted EBITDA improved to $36.2M from $9.9M YoY.Insurance revenue rose 11% YoY to $349.9M, driven by strong member retention and growth. Insurance MCR improved to 71.3% from 77.2% YoY. The company's balance sheet strengthened, with $482.8M in cash and investments as of June 30, 2024.Based on strong performance, Clover Health raised its full-year 2024 guidance. It now expects Insurance revenue of $1.35B-$1.375B and Adjusted EBITDA of $50M-$65M. The company's recent Star Rating increase to 3.5 for the 2025 payment year is expected to improve long-term profitability.
Clover Health公佈了2024年第二季度的強勁業績，總營業收入同比增長11%至35630萬。公司作爲上市公司首次實現了GAAP凈利潤，報告凈利潤爲720萬，而2023年第二季度則虧損2890萬。調整後的EBITDA同比改善至3620萬，前一年爲990萬。保險營業收入同比增長11%至34990萬，得益於強勁的會員保留和增長。保險MCR同比改善至71.3%，之前爲77.2%。截至2024年6月30日，公司資產負債表進一步加強，現金和投資總額爲48280萬。基於強勁的表現，Clover Health上調了2024年全年的指導預測。現在預計保險營業收入爲13.5億到13.75億，以及調整後的EBITDA爲5000萬到6500萬。公司近期在2025年付款年度的科創板評級提高至3.5，預計將改善長期盈利能力。
Clover Health公佈了2024年第二季度的強勁業績，總營業收入同比增長11%至35630萬。公司作爲上市公司首次實現了GAAP凈利潤，報告凈利潤爲720萬，而2023年第二季度則虧損2890萬。調整後的EBITDA同比改善至3620萬，前一年爲990萬。保險營業收入同比增長11%至34990萬，得益於強勁的會員保留和增長。保險MCR同比改善至71.3%，之前爲77.2%。截至2024年6月30日，公司資產負債表進一步加強，現金和投資總額爲48280萬。基於強勁的表現，Clover Health上調了2024年全年的指導預測。現在預計保險營業收入爲13.5億到13.75億，以及調整後的EBITDA爲5000萬到6500萬。公司近期在2025年付款年度的科創板評級提高至3.5，預計將改善長期盈利能力。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間